Latest News

Data presented at EHA 2026 showed that epcoritamab significantly improved progression-free survival and complete response rates compared with standard chemoimmunotherapy in patients with relapsed or refractory (RR) large B-cell lymphoma (LBCL).

This year’s guide, compiled from a national survey of 1700 practicing pharmacists, identifies the top recommended brands across 145 product categories, ranging from pediatric care to pain relief.

Korean and Asian manufacturers have used bemotrizinol widely in sunscreen formulations for many years.

Long-term data show that frontline zanubrutinib significantly improved second progression-free survival (PFS2) and preserved the effectiveness of subsequent BCL2 inhibitor–based therapies compared with bendamustine-rituximab in treatment-naive CLL/SLL.

Specialty pharmacy technicians address barriers in oral anticancer therapy and transitions of care through improved care coordination and therapy access.

Inlexzo Gemcitabine Intravesical System delivers sustained therapy for BCG-unresponsive NMIBC, raising complete response and avoiding cystectomy.

TIMI Study Group investigators presented new VESALIUS-CV data showing that intensive LDL-C lowering with evolocumab reduces major cardiovascular events, reinforcing the "lower is better, earlier is better" approach to lipid management.

Probiotic and prebiotic supplements shape the gut microbiome and boost gastrointestinal health and immunity.

The indication is for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or modulation-sensitive prostate cancer.

EHA 2026 data show Sonrotoclax plus zanubrutinib drives rapid, durable uMRD in frontline CLL, even TP53/del17p.

A post hoc analysis of ATTAIN-1 and ATTAIN-2 presented at ADA 2026 found orforglipron (Foundayo) significantly reduced body weight and waist circumference in women regardless of menopausal stage.

Real‑world study finds grade 1 CRS during CD20 bispecific therapy for follicular lymphoma is often safe at home, reducing hospital use.

The landscape of cardiovascular prevention is shifting from a focus on surrogate biomarkers to a more granular, image-based assessment of actual disease burden.

Data presented at EHA 2026 continue to support venetoclax plus obinutuzumab as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).

The indication is for adjuvant treatment of adults with high-risk clear cell renal cell carcinoma (RCC) following nephrectomy, based on LITESPARK-022 showing a significant improvement in disease-free survival.

Student pharmacists boost dermatology literacy in underserved communities, improving sunscreen habits, skin cancer warning recognition, and practical skin health self-care.

Landmark data from three major trials published simultaneously suggest finerenone may protect kidney function and reduce cardiovascular risk across a far broader CKD population than current guidelines recognize.

Mayo Clinic tackles medication shortages with batching and fair overtime, keeping oncology acetaminophen available in a Pharmacy Times peer review.

MRD monitoring detects microscopic disease levels to guide treatment decisions, providing actionable insights for pharmacists.

New 2026 lipid guidelines push earlier screening, PREVENT risk scoring, and tougher LDL/ApoB targets with expanded nonstatin options.

A reflection from HOPA 2026 explores medical misinformation and how oncology pharmacists can strengthen trust and guide evidence-based patient care.